沙库巴曲缬沙坦用于射血分数降低心衰住院患者的成本效益
该经济评估基于美国HFrEF患者数据,采用5状态马尔可夫模型,比较住院期间启动沙库巴曲缬沙坦与依那普利或不启动或出院后启动的成本效益。结果显示住院启动可减少心衰住院、增加质量调整寿命年并节省费用,从医疗系统角度相比继续依那普利ICER为21 532美元/QALY。
要点
- 住院期间启动沙库巴曲缬沙坦相比继续依那普利每1000例患者减少116次心衰相关住院。
- 从医疗系统角度,住院启动相比继续依那普利每年节省452美元,ICER为21 532美元/QALY。
- 从社会角度,住院启动相比不启动每年节省460美元,相比出院后启动每年节省813美元。
核心结论
- 对于HFrEF患者,住院期间启动沙库巴曲缬沙坦可能减少住院、增加质量调整寿命年并节省费用。
研究设计与样本
- 采用5状态马尔可夫模型,包含全因死亡、心衰住院和非心衰住院概率,质量调整寿命年基于Euro-QoL EQ-5D评分。
- 成本包括住院、长期护理和药物费用,贴现率3%,基础分析采用终身时间范围,从医疗系统和社会角度进行。
主要发现
- 模拟患者平均年龄63.8岁(SD 11.5)。
- 住院启动沙库巴曲缬沙坦(每年5628美元)相比出院后启动每1000例患者减少62次心衰相关住院,相比继续依那普利减少116次。
- 从医疗系统角度,住院启动相比继续依那普利每年节省452美元,相比出院后2个月启动每年节省811美元,相比继续依那普利的ICER为21 532美元/QALY。
- 从社会角度,住院启动相比不启动每年节省460美元,相比出院后启动每年节省813美元。
- 预算分析中,住院启动相比继续依那普利每例患者1年节省高达449美元,5年节省2550美元。
临床怎么用
- 对于HFrEF住院患者,可考虑在住院期间启动沙库巴曲缬沙坦以改善成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sacubitril-valsartan use reduces mortality and hospitalizations compared with enalapril among patients with chronic heart failure with reduced ejection fraction (HFrEF); however, the cost-effectiveness of these treatments when initiated during hospitalization for HF is unknown. OBJECTIVE: To estimate the cost-effectiveness of inpatient initiation of sacubitril-valsartan vs enalapril compared with no initiation or posthospitalization initiation of sacubitril-valsartan among stabilized patients with HFrEF. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation included data on US patients with HFrEF who were eligible for sacubitril-valsartan treatment from December 8, 2009, to May 15, 2018. MAIN OUTCOMES AND MEASURES: A 5-state Markov model with all-cause mortality, HF, and non-HF hospitalization probabilities was used. Quality of life was estimated using Euro-QoL EQ-5D scores. Hospitalization, long-term care, and medication costs for sacubitril-valsartan and enalapril were modeled with a discount rate of 3%. The base-case analysis included a lifetime horizon from a health care and societal perspective. RESULTS: Modeled patients were a mean (SD) age of 63.8 (11.5) years. Inpatient treatment with sacubitril-valsartan ($5628 per year) was associated with 62 fewer HF-related admissions per 1000 patients compared with outpatient initiation or 116 fewer HF-related admissions compared with continuation of enalapril treatment. From a health care system perspective, initiation of sacubitril-valsartan during hospitalization saved $452 per year compared with continuing enalapril and $811 per year compared with initiation at 2 months after hospitalization and was associated with an incremental cost-effectiveness ratio of $21 532 per quality-adjusted life-year compared with continued enalapril treatment over a lifetime. From a societal perspective, inpatient initiation was estimated to save $460 per year per patient compared with no initiation of sacubitril-valsartan and $813 per year per patient compared with initiation after hospitalization. In a budget analysis, inpatient initiation of sacubitril-valsartan was estimated to save up to $449 per person for 1 year or $2550 per person over 5 years compared with continuation of enalapril. CONCLUSIONS AND RELEVANCE: The findings suggest that, for patients with HFrEF, initiation of sacubitril-valsartan during hospitalization may be associated with reduced hospitalizations, increased quality-adjusted life expectancy, and cost savings compared with no initiation or initiation after hospitalization.
引用
- Gaziano TA, Fonarow GC, Velazquez EJ, et al. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2020. PMID: 32785628. doi:10.1001/jamacardio.2020.2822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。